okt 17, 2018: 10:45 a.m. - 11:40 a.m.
Investments in microbiome-related companies have accelerated across the past three years, demonstrating high investor expectations for results. As the first pioneering companies have pushed research into clinical development and started publishing results, those findings and new avenues beyond the gut and digestion-related therapies suggest diagnostic and treatment opportunities in inflammation, neurology, and dermatology, among others. This panel will discuss a range of microbiome-based approaches for innovations to improve patient outcomes. Topics include microbiome transplants, bioengineered probiotics, next-generation antibiotics, and microbiome-based drug discovery platforms.
Moderator: Wenyuan Shi, PhD, Chief Executive Officer and Chief Scientific Officer, Forsyth Institute